Premium
[P3–216]: PIB‐PET AS A STANDARD FOR EVALUATING THE CLINICAL ACCURACIES OF DIAGNOSING ALZHEIMER's DISEASE WITH CLINICAL DIAGNOSIS AND PLASMA BIOMARKERS
Author(s) -
Yang CheChuan,
Chiu MingJang,
Chen TaFu,
Yang ShiehYueh
Publication year - 2017
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2017.06.1429
Subject(s) - medicine , standardized uptake value , biomarker , nuclear medicine , cutoff , precuneus , positron emission tomography , pathology , radiology , chemistry , biochemistry , physics , quantum mechanics , functional magnetic resonance imaging
from ageand sex-matched controls, and from individuals with other neurodegenerative diseases. Results: Results demonstrate that detection of depleted autoantibodies in serum can readily differentiate disease subjects from ageand sex-matched controls with high overall accuracy, sensitivity, and specificity. Depletion biomarkers were able to distinguish subjects with early AD pathology at MCI from controls with 90.0% overall accuracy in the Testing Set (sensitivity1⁄488.0%; specificity1⁄492.0%). Comparable accuracies were obtained for identification of subjects with mild-moderate AD, early-stage Parkinson’s disease and multiple sclerosis. Conclusions: Results demonstrate that monitoring the disease-linked depletion of brain-reactive autoantibodies in blood has utility for early detection and staging of AD and other neurodegenerative diseases. Since autoantibody depletion may reflect neuropathological events prior to significant neurodegeneration, we hypothesize that depleted autoantibody biomarkers may be particularly useful for preclinical disease detection, perhaps years before the onset of symptoms.